- Home
- TLRY vs TNGX Comparison
TLRY vs TNGX Comparison
Compare TLRY & TNGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TLRY
- TNGX
- Stock Information
- Founded
- TLRY N/A
- TNGX 2014
- Country
- TLRY Canada
- TNGX United States
- Employees
- TLRY N/A
- TNGX N/A
- Industry
- TLRY Medicinal Chemicals and Botanical Products
- TNGX Biotechnology: Pharmaceutical Preparations
- Sector
- TLRY Health Care
- TNGX Health Care
- Exchange
- TLRY Nasdaq
- TNGX Nasdaq
- Market Cap
- TLRY 426.2M
- TNGX 351.2M
- IPO Year
- TLRY 2018
- TNGX N/A
- Fundamental
- Price
- TLRY $0.68
- TNGX $6.10
- Analyst Decision
- TLRY Hold
- TNGX Strong Buy
- Analyst Count
- TLRY 2
- TNGX 6
- Target Price
- TLRY $1.38
- TNGX $12.20
- AVG Volume (30 Days)
- TLRY 35.6M
- TNGX 2.9M
- Earning Date
- TLRY 07-28-2025
- TNGX 08-06-2025
- Dividend Yield
- TLRY N/A
- TNGX N/A
- EPS Growth
- TLRY N/A
- TNGX N/A
- EPS
- TLRY N/A
- TNGX N/A
- Revenue
- TLRY $826,656,000.00
- TNGX $40,990,000.00
- Revenue This Year
- TLRY $9.91
- TNGX N/A
- Revenue Next Year
- TLRY $5.94
- TNGX N/A
- P/E Ratio
- TLRY N/A
- TNGX N/A
- Revenue Growth
- TLRY 11.22
- TNGX 10.09
- 52 Week Low
- TLRY $0.35
- TNGX $1.03
- 52 Week High
- TLRY $2.15
- TNGX $12.02
- Technical
- Relative Strength Index (RSI)
- TLRY 75.14
- TNGX 74.27
- Support Level
- TLRY $0.39
- TNGX $5.34
- Resistance Level
- TLRY $0.55
- TNGX $5.63
- Average True Range (ATR)
- TLRY 0.04
- TNGX 0.50
- MACD
- TLRY 0.03
- TNGX -0.04
- Stochastic Oscillator
- TLRY 99.83
- TNGX 84.15
About TLRY Tilray Brands Inc.
Tilray is a Canadian producer that cultivates and sells medical and recreational cannabis. In 2021, legacy Aphria acquired legacy Tilray in a reverse merger and renamed itself Tilray. The bulk of its sales are in Canada and in the international medical cannabis export market. US exposure consists of CBD products and alcohol.
About TNGX Tango Therapeutics Inc.
Tango Therapeutics Inc is a biotechnology company. It is dedicated to discovering novel drug targets and delivering the next generation of precision medicine for the treatment of cancer. It is engaged in the business of discovering and developing precision oncology therapies. It is currently developing two MTA-cooperative PRMT5 inhibitors; TNG462 for non-CNS cancers, including pancreatic and lung cancer, and TNG456, a next-generation, brain-penetrant PRMT5 inhibitor, for CNS cancers, including GBM. Its pipeline products are PRMT5 and CoREST.